Nano Dimension (NNDM) Q2 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2024 earnings summary
23 Jan, 2026Executive summary
Achieved record Q2 2024 revenue of $15.0M, up 2% year-over-year, with gross margin improvement and significant reduction in net cash burn, despite macroeconomic headwinds in central Europe.
Announced definitive agreement to acquire Desktop Metal, aiming to create a leader in additive manufacturing with a broad, high-growth technology portfolio.
Introduced new innovations, including an Integrated Inspection System and strategic digital printing partnerships.
Significant cost reductions and improved financial strength, with a 69% reduction in net cash burn for H1 2024.
Focused on transitioning from additive manufacturing to a broader Industry 4.0 digital manufacturing strategy, emphasizing software and AI as key growth drivers.
Financial highlights
Q2 2024 revenue: $15.0M, up 2% year-over-year; H1 2024 revenue: $28.4M.
Q2 2024 gross margin: 45.4% (Q2 2023: 44.1%); adjusted gross margin: 46.6%–47%.
Q2 2024 net cash burn: $11M, reduced by 64%–69% year-over-year.
Q2 2024 adjusted EBITDA loss: $16.1M (Q2 2023: $23.5M loss).
Q2 2024 net loss: $44.3M; excluding Stratasys share changes, net loss: $12.9M.
Outlook and guidance
Management targets positive cash flow and profitability, with 64% progress toward this goal.
Desktop Metal acquisition expected to close in Q4 2024, subject to regulatory and shareholder approvals.
Combined company aims for pro forma 2023 revenue of $246M and 28% recurring revenue.
Focus remains on operational excellence, synergy realization, and driving toward positive EBITDA and cash generation post-acquisition.
Expects continued focus on integration of Desktop Metal and potential additional acquisitions over the next 12–24 months.
Latest events from Nano Dimension
- Board supports strategic review and declassification, opposes governance and director changes.NNDM
Proxy filing25 Jun 2026 - Proxy contest aims to declassify the board, restrict poison pills, and replace key directors.NNDM
Proxy filing18 Jun 2026 - Proposed merger with Infinite Epigenetics offers a 20% premium and pivots to AI-powered diagnostics.NNDM
Proxy filing17 Jun 2026 - $890M merger forms a Nasdaq-listed AI diagnostics leader targeting the $90–94B U.S. market.NNDM
M&A announcement16 Jun 2026 - Nano and Infinite plan a merger to create an AI-powered health diagnostics company, pending approvals.NNDM
Proxy filing15 Jun 2026 - Board supports declassification but opposes director removal and other governance changes.NNDM
Proxy filing11 Jun 2026 - Shareholders will vote on strategic direction, board structure, and director changes amid a proxy contest.NNDM
Proxy filing5 Jun 2026 - Strategic plan advances with cost cuts, asset sales, and a pivotal shareholder vote ahead.NNDM
Proxy filing5 Jun 2026 - Board opposes activist director replacements, prioritizing strategic review and shareholder value.NNDM
Proxy filing26 May 2026 - Q1 2026 revenue surged 106% year-over-year, but net loss deepened amid restructuring and impairment.NNDM
Q1 20267 May 2026